ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker

Vista senzilla d'ítem
dc.contributor.authorManzine, Patricia
dc.contributor.authorEttcheto Arriola, Miren
dc.contributor.authorCano Fernández, Amanda
dc.contributor.authorBusquets Figueras, Oriol
dc.contributor.authorMarcello, Elena
dc.contributor.authorPelucchi, Silvia
dc.contributor.authorDi Luca, Monica
dc.contributor.authorEndres, Kristina
dc.contributor.authorOlloquequi, Jordi
dc.contributor.authorCamins Espuny, Antoni
dc.contributor.authorCominetti, Márcia Regina
dc.date.accessioned2019-11-04T10:33:38Z
dc.date.available2019-11-04T10:33:38Z
dc.date.issued2019-04-03
dc.date.updated2019-11-04T10:33:39Z
dc.description.abstractAlzheimer's disease (AD) represents a global burden in the economics of healthcare systems. Amyloid-β (Aβ) peptides are formed by amyloid-β precursor protein (AβPP) cleavage, which can be processed by two pathways. The cleavage by the α-secretase A Disintegrin And Metalloprotease 10 (ADAM10) releases the soluble portion (sAβPPα) and prevents senile plaques. This pathway remains largely unknown and ignored, mainly regarding pharmacological approaches that may act via different signaling cascades and thus stimulate non-amyloidogenic cleavage through ADAM10. This review emphasizes the effects of natural compounds on ADAM10 modulation, which eventuates in a neuroprotective mechanism. Moreover, ADAM10 as an AD biomarker is revised. New treatments and preventive interventions targeting ADAM10 regulation for AD are necessary, considering the wide variety of ADAM10 substrates.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec691035
dc.identifier.issn0753-3322
dc.identifier.pmid30836275
dc.identifier.urihttps://hdl.handle.net/2445/143718
dc.language.isoeng
dc.publisherElsevier Masson SAS
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1016/j.biopha.2019.108661
dc.relation.ispartofBiomedicine & Pharmacotherapy, 2019
dc.relation.urihttps://doi.org/10.1016/j.biopha.2019.108661
dc.rights(c) Elsevier Masson SAS, 2019
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
dc.subject.classificationMalaltia d'Alzheimer
dc.subject.classificationProteïnes
dc.subject.classificationFarmacologia
dc.subject.otherAlzheimer's disease
dc.subject.otherProteins
dc.subject.otherPharmacology
dc.titleADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Miniatura
Nom:
691035.pdf
Mida:
797.45 KB
Format:
Adobe Portable Document Format
Descarregar

Col·leccions

Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)